In multivariate analysis, older patients, black race, advanced stage, higher grade, lack of primary surgery, and nodal metastasis were independent prognostic factors for poorer survival.
Their expression was strongly associated with high histological grade, lack of steroid hormone receptor positivity (ER and PR), and expression of basal markers (basal cytokeratins, P63, P-cadherin).
Although it is clear that her-2/ neu amplification in breast cancer is associated with high histological grade, lack of hormone receptors and a relative or absolute resistance to endocrine therapy, the data on the prognostic significance of her-2/ neu are rather controversial and still remain unsettled [ 3- 5].
Desirable criteria were having a higher education beyond tenth grade, lack of prior professional training in mental health, and a two-year commitment to the pilot and future trial.
Finally, she receives a high grade on lack of an attention span.
Though no correlation with the stage of disease (the main prognostic factor for breast cancer patients) was observed, the presence of BRCA1-2 mutations were significantly associated with some pathological characteristics (higher tumor grading, lack of expression of estrogen/progesterone receptors) which are recognized to have a negative impact on prognosis.
In mice with conditionally inactivated Brca1LoxP/LoxP and p53LoxP/LoxP, ovarian tumors arose after long latency with the majority exhibiting histological features consistent with high grade leiomyosarcomas lacking expression of epithelial, follicular or lymphocyte markers.
If after the second dose reduction of TMZ the patient experienced grade 4 neutropenia > 7 d, grade 4 neutropenia with fever (100.5 °F or higher), grade 4 thrombocytopenia, lack of recovery of ANC or platelet count to retreatment levels by the end of the 28 d, or any grade 3 or 4 nonhematological toxicity attributed to TMZ, TMZ was discontinued.
In the group with non-wide resection margins, high malignancy grade (P<0.001), lack of surgery (P<0.001) and metastasis at time of diagnosis (P<0.001) were independent prognostic indicators of poor DSS.
Results of the multivariate analyses are presented in Tables 3 and 4. In the total material, tumor depth (P = 0.046), tumor size (P = 0.045), high malignancy grade (P<0.001), lack of surgery (P<0.001), non-wide resection margins (P = 0.004) and metastasis at diagnosis (P<0.001), but none of the angiogenic markers, were significant independent prognostic indicators of DSS (Table 3).
